This week, Johnson & Johnson made headlines by revealing its $14.6 billion acquisition of Intra-Cellular Therapies. The New York City-based biotech company specializes in developing products for the central nervous system. It is most well-known for its FDA-approved drug, Caplyta.…
According to the healthcare research firm 3 Axis Advisors, companies are implementing drug price increases on over 250 medications. Some of the increases include Pfizer’s COVID-19 medication Paxlovid, Bristol Myers Squibb’s cancer cell therapies, and certain Sanofi vaccines. The firm…
Seasonal allergies are part of the sixth-leading cause of chronic illness in the United States alone is allergies. Manufacturing drugs and treating the symptoms have currently reached an estimated $18 billion industry. And it’s here again. Seasonal allergies, broadly known…
Johnson & Johnson’s success seems to be faltering recently: aside from the FDA temporarily recalling the vaccine due to instances of blood clots, Janssen’s promising study of an HIV vaccine has also fallen short of scientists’ expectations. The search for…
No matter what the risks are of complications stemming from flu vaccines, avoiding the vaccine itself is riskier. In 2018 alone, the United States experienced its deadliest influenza outbreak – 80,000 deaths, 180 of which were children. In addition, 900,000…
In the United States, there are more than 200,000 cases of seizures per year. A person who has a seizure that lasts for more than 5 minutes, or has more than 1 seizure in a 5-minute span, has a greater…
Scientists and researchers have always believed that targeting the immune system is what helps prevent type 1 diabetes. However, a new study from the University of Chicago shows that, instead, targeting beta cells may be the actual key. Triggering Type…
When COVID-19 took the world by storm, people were scared to step outside their homes. It was a time of chaos and confusion. While the pandemic has appeared to subside, an emerging concern has surfaced: a condition known as long…
An immunotherapy study on mice with cancer identified that Delta-24-ACT had a higher effectiveness rate than control treatments. Tumors developed more slowly and side effects were reduced. Pediatric osteosarcoma is a rare, but aggressive form of cancer that mainly affects…
